Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 1Breast 1

Conditions

Breast Neoplasms 4Triple Negative Breast Neoplasms 2Neoplasm Metastasis 2Carcinoma, Non-Small-Cell Lung 2Uveal Melanoma 1Small Cell Lung Carcinoma 1Recurrence 1Rectal Neoplasms 1Prostatic Neoplasms 1Pathologic Complete Response 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Melanoma 1Lung Neoplasms 1Hemangiosarcoma 1Gastrointestinal Stromal Tumors 1Fallopian Tube Neoplasms 1Esophagogastric Cancer 1Colonic Neoplasms 1Adenocarcinoma of the Prostate 1

Interventions

Oxaliplatin 67Capecitabine 60Fluorouracil 58Bevacizumab 54Gemcitabine 51Paclitaxel 50Leucovorin 50Irinotecan 40Docetaxel 39Carboplatin 39Cisplatin 38pembrolizumab 37Nivolumab 37Cetuximab 35Sunitinib 25Trastuzumab 24Radiosurgery 24Radiotherapy 21Doxorubicin 21Cyclophosphamide 21Panitumumab 20Drug Therapy 19Pemetrexed 18Everolimus 18Sorafenib 17Interleukin-2 16Fulvestrant 16Albumin-Bound Paclitaxel 16atezolizumab 15Erlotinib Hydrochloride 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Neoplasm Metastasis × STA 9090 × Clear all
NCT01560416 2026-03-03

Fulvestrant With or Without Ganetespib in HR+ Breast Cancer

Dana-Farber Cancer Institute

Phase 2 Completed
50 enrolled 14 charts
Breast

Breast Neoplasms, Neoplasm Metastasis

NCT01551693 2017-04-12

STA-9090(Ganetespib) in Patients With Unresectable Stage III or Stage IV Melanoma

Dana-Farber Cancer Institute

Phase 2 Terminated
3 enrolled 7 charts
Dermatologic

Melanoma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡